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Rapport de synthèse 
Protection contre la létalité de la sepsis à bactéries Gram-négatives 
par ciblage du récepteur TLR4 (Toll-like receptor 4) 
L'immunité innée regroupe les mécanismes moléculaires et cellulaires formant la première 
ligne de défense contre les infections microbiennes. La détection des micro-organismes 
pathogènes est assurée par des cellules sentinelles (cellules dendritiques et macrophages) qui 
jouent un rôle fondamental dans l'initiation des mécanismes de défense de l'hôte. Au contact de 
produits microbiens, ces cellules produisent un large échantillonnage de molécules, dont des 
cytokines, impliquées dans le développement de la réponse inflammatoire. La régulation de cette 
réponse relève d'un équilibre délicat, son insuffisance tant que son excès pouvant compromettre 
le devenir des patients infectés. La sepsis sévère et le choc septique représentent les formes les 
plus sévères d'infection, et leur mortalité demeure élevée (25 à 30% pour la sepsis sévère et 50 
à 60% pour le choc septique). De plus, l'incidence de la sepsis tend à augmenter, atteignant en 
2000 plus de 240 cas pour 100'000 personnes en Grande-Bretagne. La sepsis est caractérisée 
dans sa phase aiguë par une réponse inflammatoire exubérante. La plupart des thérapies visant 
à la bloquer ont toutefois montré des bénéfices incertains lors de leur application clinique. Il est 
donc impératif d'identifier de nouvelles cibles thérapeutiques. 
Les "Toll-like receptors" (TLRs) sont une famille de récepteurs qui jouent un rôle fondamental 
dans la détection des micro-organismes par les cellules du système immunitaire inné. Parmi eux, 
TLR4 est indispensable à la reconnaissance du lipopolysaccharide (LPS) des bactéries Gram-
négatives. L'interaction entre TLR4 et le LPS représentant un élément précoce de la réponse de 
l'hôte à l'infection, nous avons émit l'hypothèse que TLR4 pourrait représenter une cible de choix 
en vue du développement de nouvelles thérapies contre la sepsis. 
Dans l'objectif de valider ce concept, nous avons, dans un premier temps, démontré que des 
souris génétiquement déficientes en TLR4 étaient totalement résistantes au choc septique induit 
par Escherichia coti (E. coti), une bactérie Gram-négative fréquemment responsable de sepsis. 
Forts de cette observation, nous avons développé une molécule recombinante composée du 
domaine extracellulaire de TLR4 fusionné à la partie IgG1-Fc. Cette molécule soluble, qui inhibait 
la réponse des macrophages au LPS in vitro, a été utilisée pour générer des anticorps anti-TLR4 
chez le lapin. La spécificité et l'efficacité de ces anticorps ont été prouvées en démontrant que 
les anti-TLR4 bloquaient les signaux d'activation intracellulaire et la production de TNF et d'IL-6 
en réponse au LPS et aux bactéries Gram-négatives in vitro et in vivo. Enfin, l'efficacité des ces 
anticorps a été testée dans des modèles de sepsis chez la souris. Ainsi, l'injection prophylactique 
(-lh) ou thérapeutique ( +3h) d'anticorps anti-TLR4 réduisait la production de TNF et protégeait 
les animaux de la mort. De manière spectaculaire, ces anticorps réduisaient également la 
production de TNF et protégeaient de la sepsis à E. coti lorsqu'ils étaient administrés de manière 
prophylactique (-4h) et thérapeutique, jusqu'à 13 heures après l'initiation de l'infection. 
Ces résultats indiquent donc qu'il est possible de bloquer le développement de la réponse 
inflammatoire et de protéger du choc septique à bactéries Gram-négatives en utilisant des 
thérapies ciblant TLR4. Par ailleurs, ils suggèrent qu'une fenêtre d'opportunité de plusieurs 
heures pourrait être mise à profit pour initier un traitement chez les patients septiques. Ces 
résultats devraient encourager la poursuite des essais cliniques en cours qui visent à tester 
l'efficacité de thérapies dirigées contre TLR4 comme traitement complémentaire de la sepsis. 
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Toll-like receptor 4 (TLR4), the signal-transducing molecule of the 
LPS receptor complex, plays a fundamental role in the sensing of 
LPS from Gram-negative bacteria. Activation of TLR4 signaling 
pathways by LPS is a critical upstream event in the pathogenesis of 
Gram-negative sepsis, making TLR4 an attractive target for novel 
antisepsis therapy. To validate the concept of TLR4-targeted treat-
ment strategies in Gram-negative sepsis, we first showed that 
TLR4-t- and myeloid differentiation primary response gene 88 
(MyD88)-1- mice were fully resistant to Escherichia co/i-induced 
septic shock, whereas TLR2-1- and wild-type mice rapidly died of 
fulminant sepsis. Neutralizing anti-TLR4 antibodies were then 
generated using a soluble chi me rie fusion protein composed of the 
N-terminal domain of mouse TLR4 (amino acids 1-334) and the Fe 
portion of human lgG1. Anti-TLR4 antibodies inhibited intracellular 
signaling, markedly reduced cytokine production, and protected 
mice from lethal endotoxic shock and E. coli sepsis when admin-
istered in a prophylactic and therapeutic manner up to 13 h after 
the onset of bacterial sepsis. These experimental data provide 
strong support for the concept of TLR4-targeted therapy for 
Gram-negative sepsis. 
endotoxic shock 1 Gram-negative bacteria 1 lipopolysaccharide 1 TLR4 
The incidence of sepsis is rising, and the mortality remains high, reaching 25%-30% in patients with severe sepsis and 
50%-60% in those who develop septic shock (1). Despite initial 
encouraging results, the benefits of most new antisepsis therapies 
( e.g., drotrecogin-alpha activated, corticosteroids, intensive in-
sulin therapy, and vasopressin) remain uncertain (2). Thus, 
identification of new treatment options for septic patients re-
mains imperative. 
Endotoxin (LPS) is a major component of the outer mem-
brane of Gram-negative bacteria and a critical actor in the 
pathogenesis of Gram-negative sepsis (3). Sensing of LPS by 
innate immune cells is vital for host defenses against Gram-
negative bacteria. This multistep recognition process is initiated 
by the binding of LPS to the LPS-binding protein (LBP) that 
conveys LPS to a cell surface receptor complex composed of 
CD14, MD-2, and Toll-like receptor (TLR4) (4-10). LPS binds 
to CD14 and is then delivered to the MD-2-TLR4 complex (11). 
Structural studies of the interactions among the LPS antagonists 
lipid IVa, eritoran (E5564), MD-2, and TLR4 have revealed that 
LPS binds to an hydrophobie internai pocket of MD-2 that itself 
is bound to the concave surface of the N-terminal and central 
domains of TLR4 (12, 13). Binding of LPS to the MD-2-TLR4 
complex causes TLR4 dimerization and sets off intracellular 
signaling initiated by the Toll/IL-1 receptor (TIR) domain-
containing adaptor molecules MyD88, TIR domain-containing 
adaptor-inducing IFN-{3 (TRIF), TIR domain-containing adap-
tor protein (TIRAP), and TRIF-related adapter molecule 
(TRAM) (14). The TIRAP-MyD88-dependent signaling path-
way activates NF-1<B and the MAPKs (ERK-1/2, JNK, and p38), 
resulting in the expression of numerous genes encoding cyto-
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kines and other inflammatory molecules. The TRAM-TRIF-
dependent signaling pathway activates IFN response factor 3, 
inducing the production of type 1 IFN. Cytokines, chemokines, 
and type 1 IFN are critical to the host antimicrobial defense 
response. 
Regulation of innate immune responses is a delicate balancing 
act, and dysregulated innate immune reactions, by either default 
or excess, have dramatic consequences for the infected host, as 
seen in severe sepsis. Given its central role in the pathogenesis 
of Gram-negative sepsis, TLR4 is a target of choice for the 
development of nove! antisepsis therapies. Here we report that 
anti-TLR4 antibodies raised against the ectodomain of TLR4 
improved survival in experimental models of Gram-negative 
bacterial sepsis when administered both prophylactically and 
therapeutically. 
Results 
TLR4 and MyD88 Are Critical Effector Molecules in Escherichia coti 
Sepsis. To validate the concept of immunomodulation of the 
TLR4 activation pathway as a treatment strategy for Gram-
negative sepsis, we studied cytokine production profiles and 
survivais ofwild-type (WT), TLR4-1-, TLR2-1-, and MyDss-1-
mice in a mode! of lethal peritonitis induced by E. coti, the most 
common cause of Gram-negative sepsis (15). Given the critical 
role played by TLR2 in the sensing of Gram-positive bacteria and 
some Gram-negative bacteria (16, 17), we used TLR2-1- mice as 
contrais. At 4 h after bacterial challenge, very high concentra-
tions ofbioactive TNFwere detected in the circulation of the WT 
and TLR2-1- mice (median, 6.5 ng/mL vs. 9.7 ng/mL; P = .5) 
(Fig. lA). In contrast, TNF was either strikingly reduced or 
undetectable in the TLR4-1- and MyDss-1- mice (0.5 and 0 
ng/mL, respectively; P = .002). Likewise, circulating levels of 
bioactive IL-6 were much higher in the WT and TLR2-1- mice 
(8.0 and 10.6 ng/mL; P = .31) than in the TLR4-i- and 
MyDss-1- mice ( 4.2 and 2.0 ng/mL; P = .04 and .002) (Fig. lB). 
Blunted proinflammatory responses were associated with full 
survival of the TLR4-1- and MyDss-1- mice, whereas all but 1 
of the WT and TLR2-1- mice died (P < .001) (Fig. lC). This 
indicates that the activation ofTLR4, but not ofTLR2, is critical 
to the host response to E. coli sepsis. 
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Fig. 1. TLR4-deficient and MyD88-deficient mice are protected from lethal 
Gram-negative bacterial sepsis. (A-C) wr, TLR2-1-, TLR4-1-. and MyD80-1-
C57BU6 mice were injected i.p. with 2 x 109 du of E. coli 018 and treated with 
antibiotics as described in Materials and Methods. Plasma concentrations of 
TNF (A) and IL-6 (8) were measured 4 h after bacterial challenge. The hori-
zontal line represents the median cytokine concentration (TNF: P < .005 for 
TLR4-I- or MyD00-1- vs. wr or TLR2-1-. p = '15 for TLR4-1- vs. MyD00-1-. and 
P = .48 for wrvs. TLR2-1-; IL-6: P < .05 and< .005 for TLR4-1- and MyD00-1-
vs. wr or TLR2-1-. p .13 for TLR4-1- vs. MyD00-1-. and p = .31 for wr vs. 
TLR2-1-). (C) Survival of TLR4-1-. MyD00-1-. TLR2-1-. and wr mi ce (P < .001). 
Data points are from 1 experiment (n = 6 to 7 mice per treatment groups). 
Chimeric Mouse TLR4-Human Fe Fusion Protein. TLR4 is composed 
of N-terminal, central, and C-terminal domains. MD-2 binds to 
the concave surface of the N-terminal and central TLR4 do-
mains (12, 18). To obtain anti-TLR4 antibodies, we first gener-
ated a soluble recombinant chimeric protein composed of the 
N-terminal half of the mouse TLR4 ectodomain (amino acids 
1-334) fused to the Fe domain of human IgGl (mTLR4-Fc). The 
recombinant mTLR4-Fc protein was produced in HEK 293T 
cells to ensure posttranscriptional modifications. In the pres-
ence of serum as a source of soluble MD-2, LPS was shown to 
bind to mTLR4-Fc (Fig. SlA). mTLR4-Fc also was shown to 
inhibit LPS-induced TNF release in a whole-blood assay (Fig. 
S1B). Together, these data indicate that the recombinant 
mTLR4-Fc protein expresses TLR4 domains critical for the 
binding of MD-2-LPS complexes, and that mTLR4-Fc acts as 
a decoy soluble receptor capable of inhibiting the activation of 
membrane-bound TLR4-MD2 receptor complex by LPS. 
Anti-TLR4 Antibodies lnhibit lnnate Immune Responses lnduced by LPS 
and Gram-Negative Bacteria. mTLR4-Fc was used to generate high 
titers of rabbit anti-mouse TLR4 antibodies, which were purified 
through a 3-step procedure as described in Materials and Meth-
ods. Specificity was confirmed by demonstra ting tha t an ti-TLR 4 
antibodies recognized mTLR4-Fc but not an irrelevant chimeric 
fusion protein (mGITR-Fc) by ELISA (Fig. 24), and also by the 
staining of WT but not TLR4-1- mouse peritoneal macrophages 
by flow cytometry (Fig. 2B). We then studied the capacity of 
anti-TLR4 antibodies to inhibit responses of innate immune cells 
stimulated with LPS in vitro. Compared with contrai antibodies, 
anti-TLR4 antibodies strongly inhibited LPS-induced intracel-
lular signal transduction, as demonstrated by the luciferase 
reporter activity driven by NF-KB in RAW 264.7 macrophages 
(Fig. 2C) and by phosphorylation of ERK-1/2 in bone marrow-
derived macrophages (Fig. 2D). Anti-TLR4 antibodies also 
markedly inhibited LPS- and E. coli-induced TNF and IL-6 
production by RAW 264.7 macrophages and by mouse whole 
blood (Fig. 2E-H and data not shown). In contrast, anti-TLR4 
antibodies did not affect signal transduction or cytokine pro-
duction by macrophages or by whole blood stimulated with other 
TLR ligands, such as Pam3CSI~ (Fig. 2C and D), peptidoglycan 
(Fig. 2E), and cytosine guanine dinucleotide (CpG) oligonucle-
otides (ODNs) (Fig. 2F-H). The biological activity of anti-TLR4 
antibodies also was demonstrated through a proof-of-principle 
A 1.5 D mTLR4-Fc 
llll mGITR-Fc 
B C ~ 12 11111 Contrai 1l D Anti-TLR4 D LPS Pam3CSK4 
:il 1 
ô 
0 .5 
E 6 
~ 4 
.s 
IL 
~ 2 
100 
Anlibody dilution 
1111 Contrai 
D Anli-TLR4 
0-'---""-----==>Ji"--'----""----' 0 1 10 100 10 
LPS (ng/ml) PGN 
(µg/ml) 
ë 
" 8 
Qi 
0 
Q) 
~ 8 
Q) 
'li 
-'" 
i 
Antî· Contrai Anti~ Contrai 
TLR4 TLR4 
p-ERK1/2 ~:;;;:::~~~~~:::;; 
ERK1/2 '-------='--=-=-=i 
100 101 102 10' 10• 
Fluorescence intensity 
Q) 0 
Cl'. Medium LPS Pam3CSK4 
F Ill Contrai i 2;WJ1DAnti-TLR4 
IL 1 
i':: 0 .. •• 
0 10 100 0.1 
LPS (ng/ml) CpG 
(µM) 
G llllControl 
,';r-,i~ [;, t 4 .. 
z 
1- 2 
0 Medium E. co/i CpG 
018 
H Ill Contrai 
c- 600Li]Anti-TLR4 
-§,400 
& 
"' :d 200 ,, 
O Medium E. coli CpG 
018 
Fig. 2. Anti-TLR4 antibodies bind to TLR4 and inhibitthe activation of macrophages induced by LPS. (A) Anti-TLR4 antibodies binding to immobilized mTLR4-Fc 
but not to mGITR-Fc by ELISA. (8) Flow cytometry analysis of anti-TLR4 antibodies (gray area) binding to wr (i.e., TLR4 +i+) (Upper) but not to TLR4-1- (Lower) 
thioglycollate-elicited mouse peritoneal macrophages. Background staining using control antibodies is shown in white. (C) NF-KB activity in RAW 264.7 
macrophages transientlytransfected with a trimeric KB site luciferase reporter vector and preincubated for 30 min with anti-TLR4 and control antibodies (100 
µg/ml) before stimulation with LPS (10 ng/ml) or Pam3CSK4 (2 µg/ml) for 18 h. Data on relative luciferase activity are expressed as mean :±: SD of 4 replicates 
from 1 representative experiment. *P = .001 for anti-TLR4 versus control antibodies. (O) Western blot analyses of phosphorylated-ERK1/2 {p-ERK1/2) and total 
ERK1/2 expression in bone marrow-derived macrophages preincubated for 20 min with 10 or 100 µg/ml of anti-TLR4 or control antibodies before stimulation 
with LPS (1 ng/ml) and Pam3CSK4 (1 µg/ml) for 20 min. (E-H) TNF and IL-6 production by RAW 264.7 macrophages (E) or mouse whole blood (F-H) preincubated 
for 30 min with anti-TLR4 or control antibodies (100 µg/ml) before stimulation with 100 ng/ml of LPS, 10 µg/ml of PGN, O. 1 µM CpG ODN (CpG), or 106 du/ml 
of heat-killed E. co/i 018 for 4 h. Data are expressed as mean :±: SD of triplicates from 1 representative experiment. *.005 < P < .05 and **P < .005for anti-TLR4 
versus control antibodies. 
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Fig. 3. Anti-TLR4 antibodies inhibit cytokine production and protect mice 
from lethal endotoxemia when administered prophylactically and therapeu-
tically. (A-C) Mice injected i.v. with 40 mg/kg of anti-TLR4 or control antibodies 
and TLR4-1- mi ce were sensitized with D-galactosamine 15 min before an i.v. 
injection of 50 ng of E. coli 0111 :84 LPS. Plasma concentrations ofTNF (A) and 
of IL-6 (8) were measured 1 h after LPS injection. The horizontal line represents 
the median cytokine concentration. Control versus anti-TLR4 antibodies, P < 
.0001 for TNF and P = .005 for IL-6. (Q Prophylaxis. Survival of mice treated 
with anti-TLR4 versus control antibodies (n = 19 and 21 mice per treatment 
group; P = .0001) and TLR4-1- mice (n = 8). Data points are from 4 indepen-
dent experiments for antibody evaluation. (O) Therapy. Survival of BALB/c 
mice treated with anti-TLR4 or control antibodies (40 mg/kg i.p.) 4 h after i.p. 
injection of 1 mg of E. co/i 0111 :84 LPS (P = .025). Data points are from 1 
experiment (n = 8 mice per treatment group). 
type experiment demonstrating that immunoneutralization of 
TLR4 activity, like TLR4 deficiency, increased circulating bac-
terial counts and mortality in nonsevere E. coti peritonitis and 
Klebsiella pnewnoniae pneumonia models (Fig. S2). Together, 
these results provide compelling evidence that anti-TLR4 anti-
bodies recognize membrane-bound TLR4 and inhibit innate 
immune responses of cells stimulated with LPS or Gram-
negative bacteria in vitro and in vivo. 
Anti· TLR4 Antibodies Protect Against Lethal Endotoxemia. Affording 
protection against lethal endotoxemia is important in patients 
with fulminant meningococcemia associated with high levels of 
circulating endotoxin (19). We explored the protective capacity 
of the anti-TLR4 antibodies in a mode! of endotoxemia in 
D-galactosamine-sensitized mice. Consistent with the results 
observed in vitro, anti-TLR4 antibodies given i.p. 15 min before 
an LPS challenge almost completely eliminated TNF production 
(P < .0001) (Fig. 3A) and strongly reduced IL-6 production (P = 
.005) (Fig. 3B). Of note, the amount of TNF produced by mice 
treated with anti-TLR4 antibodies was comparable to that 
produced by TLR4-1- mice. Prevention of cytokine release by 
anti-TLR4 was associated with improved survival (con trois, 94% 
in anti-TLR4 and 92% in TLR4-1-, compared with 37% in 
contrais; P = .0001) (Fig. 3C). Time-course analyses of the 
magnitude and duration ( up to 60 h) of the inhibition of cytokine 
production and protection afforded by a single dose of anti-
TLR4 antibodies against lethal endotoxemia (Table Sl) suggests 
the possibility that anti-TLR4 treatment also could work when 
given after the LPS challenge. Indeed, as shown in Fig. 3D, 
anti-TLR4 treatment remained fully protective when given up to 
4 h after LPS exposure (P = .025). Anti-TLR4 antibodies did not 
protect mice from taxie shock induced by Pam3CS~, a Gram-
positive lipopeptide and activator of TLR1-TLR2 heterodimers 
(Fig. S3), providing evidence of TLR4 specificity. 
Anti-TLR4 Antibodies Protect Against lethal Live E. co/i Sepsis. We 
studied the impact of anti-TLR4 antibodies in a classical Gram-
2350 1 www.pnas.org/cgi/doi/1O.1073/pnas.0808146106 
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Fig. 4. Prophylactic and therapeutic administration of anti-TLR4 antibodies 
protect mice from lethal Gram-negative bacterial sepsis. (A-0) BALB/c mice 
were injected i.p. with anti-TLR4 or control antibodies (160 mg/kg for A-C and 
200 mg/kg for O) given before (prophylactically; A and 8) or after (therapeu-
tically; C and O) an i.p. injection of a high (2 x 109 du) inoculum (A-C) or low 
(2 x 105 du) inoculum (O) of E. co/i018. (A) Plasma concentrations of TNF and 
IL-6 were measured 4 h after the bacterial challenge. The horizontal line 
represents the median cytokine concentration. P< .005 forTNF and IL-6. (8-0) 
Survival of mice treated prophylactically (8) (at -4, -0.5, and + 4 h) or 
therapeutically either early ( + 1 and + 4 h) (C) or late ( + 13 h) (0). P < .0001, 
.02, and .03, respectively. Data points are from 1 experiment (n = 10-12 mice 
per treatment group). 
negative bacterial sepsis mode! induced by an i.p. injection oflive 
E. coti, the most frequent cause of bacterial sepsis in humans 
(15). Prophylactic administration of anti-TLR4 antibodies led to 
a 5-fold reduction in the median circulating TNF level ( 4.2 ng/mL 
in contrais vs. 0.8 ng/mL in anti-TLR4; P < .005), a 2-fold 
reduction of IL-6 (11.1 vs. 6.3 ng/mL; P < .005) (Fig. 4A), and 
a striking increase in survival (0 vs. 80%; P < .0001) (Fig. 4B). 
To test anti-TLR4 antibodies in a condition mimicking their 
clinical use in patients with sepsis, we administered therapy after 
the onset of infection in 2 different severity models. In the first 
mode!, mice were challenged with a high E. coti inoculum (2 X 
109 cfu), which caused a fulminant, rapidly lethal sepsis. Delayed ( + 1 h) administration of anti-TLR4 was associated with in-
creased survival rate (30% vs. 10%; P = .02) and prolonged 
survival time (median time to death, 30 h in anti-TLR4 mice vs. 
4 h in contrai mice; P = .008) (Fig. 4C). In the second mode!, 
mice were challenged with a lower E. coli inoculum (2 X 105 cfu ), 
which caused an acute but less fulminant course of sepsis. 
Initiation of anti-TLR4 therapy as muchas 13 h after the onset 
of infection, at which point clinical signs of sepsis were estab-
lished and circulating levels of endotoxin were elevated (mean ± 
SD, 13.1 ± 15.2 ng/mL; range, 2.91-45.7 ng/mL; n = 7), 
remained associated with improved survival (75% vs. 30%; P = 
.03) (Fig. 4D). Together, these results demonstrate that anti-
TLR4 antibodies are highly efficacious as adjunctive therapy for 
E. coti sepsis, with a window of clinical application including bath 
prophylactic and therapeutic intervention modalities. 
Discussion 
Major breakthroughs in our understanding of the pathogenesis 
of Gram-negative sepsis are providing new treatment opportu-
nities for severe sepsis and septic shock. For example, TLR4 and 
MD-2 have recently emerged as critical sensors ofLPS ( 4-6, 20). 
As the signal-transducing component of the LPS receptor com-
plex, TLR4 is a very attractive target for new antisepsis therapy. 
Here we provide compelling experimental evidence supporting 
the efficacy of anti-TLR4 adjunctive therapy for Gram-negative 
sepsis. Using a recombinant chimeric fusion protein composed 
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of the N-terminal and central domains (amino acids 1-334) of 
the extracellular part of TLR4 and the Fe portion of human 
IgGl, we produced anti-TLR4 antibodies that inhibited LPS-
induced intracellular signaling and cytokine production and 
protected mice from lethal endotoxic shock and E. coli bacterial 
sepsis, even when treatment was delayed for several hours after 
endotoxemia or the onset of sepsis. Resolution of the crystal 
structures of the human and mouse TLR4-MD-2 complexes 
has provided an explanation for the mode of action of these 
anti-TLR4 antibodies (12). Based on the identification of the 
residues implicated in the contact between TLR4 and MD-2 and 
present in the chimeric mTLR4-Fc immunogen, anti-TLR4 
antibodies likely impede the binding of the MD-2-LPS complex 
to TLR4. 
The protective effects of the anti-TLR4 therapy were impres-
sive and in some respects unique. Previous studies conducted 
with anti-LBP or anti-CD14 antibodies in experimental models 
of endotoxic shock and Gram-negative bacterial sepsis uniformly 
failed to show protection when treatment was administered after 
LPS ( anti-LBP) or simultaneously with or shortly after bacterial 
challenge (anti-LBP and anti-CD14) (21-23). In contrast, anti-
TLR4 antibodies were found to prevent death from endotoxic 
shock even when treatment was delayed for as much as 4 h after 
the LPS challenge (Fig. 3D). These findings provide strong 
support for an anti-TLR4 treatment strategy in patients with 
fulminant meningococcemia associated with high Ievels of cir-
culating endotoxin in whom anti-LPS (i.e., recombinant bacte-
ricidal/permeability-increasing protein) and anti-sepsis (i.e., ac-
tivated protein C) therapies have failed (24, 25). Unlike 
monoclonal antibodies raised against TLR4-MD-2, which work 
only when administered prophylactically in bacterial sepsis (26, 
27), anti-TLR4 antibodies afforded remarkable protection 
against lethal E. coli sepsis when treatment was delayed for as 
much as 13 h after the onset of infection (Fig. 4D), offering a 
much broader window of therapeutic intervention. 
Sorne Gram-negative endotoxin species also are sensed by 
TLR2 (28-30), and several bacterial components (i.e., pepti-
doglycan, lipopeptides, flagellin, CpG DNA motifs) are recog-
nized by other members of the TLR family besides TLR4, 
including TLRl, TLR2, TLR5, TLR6, and TLR9. These prop-
erties support the potential need for combined anti-TLR ther-
apies. Along these lines, Spiller et al. (27) recently proposed the 
need for dual blockade of TLR2 and TLR4-MD-2 to protect 
against Gram-negative sepsis when therapy is initiated after the 
onset of infection. Challenging the concept of a need for dual 
TLR2 and TLR4-MD-2 targeted therapy (27), our findings 
demonstrate that TLR2 clearly was not a key player in the 
pathogenesis of Gram-negative sepsis. Indeed, unlike the 
TLR4-/- mice, the TLR2-1- mice produced an abundant 
amount of cytokines during E. coli sepsis and had a rapidly fatal 
clinical course identical to that of WT mice (Fig. 1), an obser-
vation consistent with recent in vitro data indicating that TLR4-
MD-2 is the main recognition system for enterobacteria Iike E. 
coli and K pneumoniae (29). Furthermore, the sole blockade of 
TLR4 was sufficient to protect against Gram-negative sepsis 
caused by E. coti, even when therapy was administered long after 
the start of sepsis. Although somewhat overlooked, prophylactic 
anti-TLR4 monotherapy also has been shown to be protective 
against lethal E. coti infection (27), suggesting that administra-
tion of repeated doses of anti-TLR4 antibody might increase 
survival when given therapeutically, as shown in the present 
study. Other plausible reasons for the divergent results between 
our study and the study of Spiller et al. (27) could include the 
much broader antibody repertoire of polyclonal antibodies; the 
use of different E. coli and mouse strains, bacterial inocula, and 
antibiotic classes; and differences in the timing of antibiotic 
administration. 
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An anti-TLR4 treatment strategy also is supported by recent 
data obtained with eritoran (E5564), a synthetic LPS antagonist 
that binds to MD-2 (12, 31), and TAK-242, a cyclohexene 
derivative that inhibits TLR4-mediated signal transduction, 
which prevented lethality in experimental models of LPS shock 
or bacterial sepsis in rodents (32, 33). At a time when most 
antisepsis clinical trials have yielded frustratingly negative re-
sults (2, 34), our experimental data !end strong support to 
TLR4-targeted therapy (i.e., eritoran and TAK-242) currently 
under development in patients with Gram-negative sepsis. 
Materials and Methods 
Mice. Eight- te 10-week-old female OF1, BALB/c, and C57BU6 mice were 
purchased from Charles River Laboratories. MyD88-1-, TLR2-1-, and TLR4+ 
C57BU6 mice have been described previously (4, 17, 35). Mice were bred and 
housed in specific pathogen-free conditions in groups of 5-10 mice per cage 
with free access to food and water. Ali animal procedures were approved by 
the Office Vétérinaire du Canton de Vaud (authorization numbers 876.5, 
877.5, and 1009.4) and performed in accordance with the institutional guide-
lines for animal experiments. 
Cells and Reagents. HEK 293T cells were cultured in OptiMEM medium. RAW 
264.7 murine macrophages were grown in RPMI medium 1640 containing 2 
mM glutamine. Meuse bene marrow-derived macrophages (BMDMs) were 
obtained as described previously (36) and cultured in lscove's modified Dul-
becco's medium containing 2-mercaptoethanol. Ali media were supple-
mented with 10% heat-inactivated FCS (Seromed) and antibiotics. Thiogly-
collate-elicited peritoneal macrophages were harvested from mice 3 days 
after i.p. injection of 2 ml of 3% thioglycollate solution (BD Biosciences). 
Heparinized blood was collected from OF1 mice. Where indicated, cells, or 
blood were incubated with 1-100 ng/ml of Salmonella minnesota Ultra Pure 
LPS (List Biologicals Laboratories), 10 µg/ml of Staphylococcus aureus pepti-
doglycan (PGN; Sigma), 1 µg/ml of Pam3CSK4 (EMC microcollections), or 0.1 
µM CpG ODN (Coley Pharmaceutical Group). 
Soluble Chimeric mTLR4·Fc. A DNA fragment encoding for amine acids 1-334 
of mouse TLR4 (mTLR4) was amplified by PCR using the Expand High-Fidelity 
PCR system (Roche Applied Science) and mT4Fc sense (TCCGTCGACGCCAC-
CATGATGCCTCCCTGGCTC) and mT4Fc antisense (GGGTCGACTGATAAGGAT-
TGCCATTTGAA) oligonucleotides containing a Sail site (indicated in bold). The 
amplicon was cloned into the pGEM-T Easy vector (Promega), sequenced, 
excised with Sali, and subcloned upstream of the sequence encoding for the 
human lgG1 Fe segment into the pFc plasmid (Apotech). Recombinant 
mTLR4pFc-expressing vector was transfected into HEK 293T cells using the 
calcium-precipitation method. The transfected HEK 293T cells were incubated 
for 3 days in OptiMEM medium (lnvitrogen). Supernatant was collected and 
centrifuged, and soluble recombinant mTLR4-Fc fusion protein was purified 
by protein A (APBiotech) immunoaffinity chromatography. The molecular 
weight of the recombinant protein was verified by SDS/PAGE analysis, and the 
presence of the Fe fragment of human lgG was confirmed by Western blot 
analysis using the mouse GG-7 Fc-specific anti-human lgG antibody (Sigma). 
Anti·TLR4 Antibodies. Anti-TLR4 antibodies were produced in New Zealand 
White rabbits by repeated immunization with 100 1,g of purified mTLR4-Fc 
fusion protein in Specol. Anti-TLR4 antibody titers were measured by ELISA as 
described below. Rabbits were bled when anti-TLR4 antibody titers reached a 
plateau. Nonimmune and anti-mTLR4-Fc antibodies were isolated from rabbit 
serum by protein A affinity chromatography following the manufacturer's 
recommendations (GE Healthcare). Affinity-purified anti-mTLR4 antibodies 
used in some experiments were isolated from anti-mTLR4-Fc sera using a 
3-step procedure that included lgG purification using protein A chromatog-
raphy, followed by anti-Fc antibody depletion using an mGITR-Fc-coupled 
affinity column and a final step of mTLR4-specific antibody purification 
using a mTLR4-Fc-coupled affinity Hi-trap NHS·activated column (APBio-
tech). The endotoxin content of the purified antibodies was 100 pg per mg 
of antibodies as measured by the limulus amebocyte lysate assay (Charles 
River Laboratories). 
ELISA for Measurement of Anti·TLR4 Antibodies. First, 96-well plates were 
coated ov~rnight at4 'Cwith 1 µ.g/ml of mTLR4-Fcor mGITR-Fcfusion prote in 
as a negat1ve contrai. Afterwashrng, the plateswere incubated for 1 h at37 'C 
with PBS containing 5% FCS and then with serial dilutions of preimmune or 
immune rabbit serum, before a final incubation step with HRP·conjugated 
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goat anti-rabbit lgG (Pierce). Peroxidase activity was assessed with the TMB 
(3,3', 5,5'-tetramethylbenzidine) substrate kit (Pierce), with optical density 
measured at 450 nm. 
Flow Cytometric Analysis. After Fe receptors were blocked with 2.4G2 hybrid-
oma supernatant, expression of TLR4 was evaluated by first incubating thio-
glycollate-elicited peritoneal macrophages with affinity-purified anti-TLR4 or 
control antibodies and then with phycoerythrin-conjugated sheep anti-rabbit 
lgG (Serotec). Acquisition and analysis were performed with a FACSCalibur 
flow cytometer (BD Biosciences) and FlowJo 8.5.3 software (FlowJow). 
Cytokine Measurements. RAW 264.7 murine macrophages were plated at a 
density of 2 x 104 cells per well in 96-well culture plates (Costar). A whole-
blood stimulation assay was performed in the 96-well culture plates in a total 
volume of 200 µL (90 i;L of blood and 110 µLof RPMI medium 1640). Ce lis and 
whole blood were stimulated for 4 h with LPS, PGN, Pam3CSK4, or CpG ODN 
with or without a 30-min preincubation with anti-TLR4 or contrai antibodies. 
The concentrations ofTNF and IL-6 in cell culture supernatants were measured 
as described previously (37). 
Transient Transfection. RAW 264.7 macrophages grown at 60% confluency in 
24-well plates (Costar) were transiently transfected with 500 ng of a trimeric 
"B site-pGL2 luciferase vector and 100 ng of the Renilla pRL-TK vector (Pro-
mega) as described previously (38). At 8 h after transfection, cells were 
preincubated for 30 min with 100 µg/ml of either anti-TLR4 or control 
antibodies and then stimulated for 18 h with 10 ng/ml of LPS or 2 µg/ml of 
Pam3CSK4• Luciferase and Reni/la luciferase activities were measured using the 
Dual-Luciferase Reporter Assay System (Promega). Results are expressed as 
relative luciferase activity (ratio of luciferase activity to Reni/la luciferase 
activity). 
Western Blot Analyses. BMDMs were plated at a densityof 2 x 106 cells perwell 
in 6-well culture plates and incubated as described in Fig. 20. Cell lysates were 
fractioned through 12% SDS/PAGE gels and then transferred onto nitrocel-
lulose membranes. Membranes were incubated overnight at 4 'C with anti-
bodies specific for ERK1/2 (Cell Signaling Technology). After washing, 
membranes were incubated for 1 h with secondary HRP-conjugated goat 
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anti-rabbit lgG. Signais were measured using the ECL Western blot analysis 
system (GE Healthcare). Membranes were then stripped and reprobed with 
anti-ERK1/2 antibodies (Cell Signaling Technology). 
Endotoxic Shock and Bacterial Sepsis Models. Two models of endotoxic shock 
were used. ln the low-dose LPS model, mice were sensitized with an i.p. 
injection of 40 mg of D-galactosamine (Sigma) administered 15 min before an 
i.v. injection of 50 ng of E. coti ultra Pure 0111 :84 LPS (List Biological Labo-
ratories). ln the high-dose model, mice were injected i.p. with 1 mg of E. coti 
0111 :B4 LPS. 
ln the bacterial sepsis models, bacterial peritonitis was induced by an i.p. 
injection of either 2 x 1os or 2 x 109 du of E. co/i018. Miceweretreated with 
ceftriaxone (100 mg/kg i.p.) plus gentamicin (20 mg/kg i.p.) given at + 15 min 
(ceftriaxone), +4 h (ceftriaxone and gentamicin) and then every 12 h in mice 
inoculated with 2 x 109 cfu of E. coti018 and at + 12 h (ceftriaxone) and+ 24 h 
(ceftriaxone and gentamicin) and then every 12 h in mi ce inoculated with 2 x 
105 cfu of E. coti 018. Anti-TLR4 and control antibodies were administered 
either prophylactically or therapeutically, as described in Fig. 4. Mice were 
monitored at least twice daily until death or complete recovery occurred. 
Blood samples were harvested from the tail vein for quantification of circu-
lating bacteria and measurements of serum TNF and IL-6 concentrations. 
Endotoxin Measurements. Endotoxin was measured in heparinized mouse 
plasma using Limulus Amebocyte Lysate Test Cartridges and the Endosafe PTS 
Portable Test System (Charles River Laboratories). The detection li mit of the 
assay was 5 pg/ml. 
Statistical Analyses. Comparisons among treatment g'roups were performed 
using Fisher's exact test for categorical data and the Mann-Whitney test for 
continuous variables. The Kaplan-Meier method was used for survival, and 
differences were analyzed by the log-rank sum test. Ali analyses were per-
formed using GraphPad PRISM. Ali reported P values are 2-sided, and values 
.05 are considered to indicate statistical significance. 
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Fig. 51. mTLR4-Fc binds to LPS and inhibits LPS-induced TNF production by whole blood. Soluble recombinant mTLR4-Fc fusion protein was produced and 
purified as described in Materials and Methods. mGITR-Fc protein (Apotech) was produced under similar conditions and used as a negative contrai. (A) The 
96-well plates (MaxiSorb; Nunc) were coated overnight at room temperature with mTLR4-Fc (open symbols) or mGITR-Fc (closed symbols), each at 25 µg/mL in 
200 µLof PBS. After extensive washing, the plates were incubated for 1 h at 37 'C successively with PBS containing 5% FCS, serial dilutions of LPS from E. co/i 
0111 :B4 (Sigma Aldrich), anti-LPS mouse monoclonal antibody (clone D6B3, at 10 µg/ml), and HRP-conjugated goat anti-mouse lgG (Pierce). Peroxidase activity 
was measured using the TMB substrate kit (Pierce). Data are reported as mean ± SD oftriplicates from 1 representative experiment. (B) LPS (0, 1, and 10 ng/mL) 
was preincubated for 15 min at 37 'C with 10 µg/mL of either mTLR4-Fc (white bars) or mGITR-Fc (black bars), and then added into 96-well plates containing 90 
1,L of heparinized whole blood from OF1 mi ce in a final volume of 200 µL. After 4 h of stimulation, supernatants were collected and used to quantifyTNF release 
using the WEHI 164 clone 13 mouse fibrosarcoma cell line. Results are reported as mean ± SD of 3 independent determinations. P < .001 for mTLR4-Fc versus 
mGITR-Fc at ail LPS concentrations. 
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Fig. 52. Anti-TLR4 antibodies increase mortality of nonsevere Gram-negative infections. (A and B) WT and TLR4·1- C57BU6 mice (n = 6) were injected i.p. with 
4 x 102 cfu of E. co/i 018. (A) Survival of WT and TLR4·1· mice. P = .001. (8) Bacterial counts measured in blood at 3, 24, and 48 h after infection. Data are reported 
asmean :t SD of 6samples. *P< .0001. (Cand D) OF1 mice (n = 20)were injected i.v. with 40 mg/kg of anti-TLR4orcontral antibodies 30 min before an i.p. injection 
of 103 cfu of E. coli 018. (C) Survival of mice. P < .0001. (D) Bacterial counts measured in blood at 2, 4, 6, and 24 h after infection. Data are reported as mean :t 
SD of 3 or 4 samples. *P = .04; **P = .007. (E) Survival of mice (n = 7 or 8) injected intranasally with 5.6 x 102 cfu of K. pneumoniae and i.p. with 40 mg/kg of 
anti-TLR4 or contrai antibodies at 24 h postinfection. P = .002. 
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Fig. 53. Anti-TLR4 antibodies do not pratect from Pam3CSK4-induced toxic shock. Survival of mice (n = 12) treated with anti-TLR4 or contrai antibodies (50 
mg/kg i.v.) administered 1 h before Pam3CSK4 (1.6 mg/kg i.p.; EMC micracollections) and D-galactosamine (1 g/kg i.p.; Sigma). 
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Table 51. Time-course analysis of the magnitude and duration of cytokine production inhibition and protection afforded by a single 
dose of anti-TLR4 antibody in an endotoxic shock mode! 
Time (in hours) between antibody administration and LPS challenge 
0.2 6 24 48 60 120 
TNF, pg/ml, median (range) 131 (0-655) 236 (115-1074) 31 (0-155) 51 (47-116) 949 (209-1923) 11417 (1556-29800) 
IL-6, pg/ml, median (range) 1035 (246-1426) 664 (291-1184) 291 (145-558) 789 (597-1599) 1576 (1116-2846) 4248 (2898-10066) 
Survival, % 95.2 100 100 100 100 0 
D-galactosamine-sensitized OF1 mice were given 50-mg/kg injections of anti-TLR4 antibodies 0.2, 6, 24, 48, 60, and 120 h before a 50-ng i.v. injection of LPS 
0111 :B4. Concentrations of TNF and IL-6 were measured 1 h after the LPS challenge, as described in Materials and Methods. Survival was assessed 7 days after 
the LPS challenge; ail deaths occurred within the first 72 h. 
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